Blog & Resources Camargo Blog April 10th, 2013

New PDUFA V Meeting Timelines

PDUFA V ushered in new industry and FDA commitments. Among these are changes in meeting timelines. A significant change from PDUFA IV is the timeline for Type A meetings. Under PDUFA IV the meeting package was due 30 days in advance of the meeting. Now, under PDUFA V, this package is due at the time of the meeting request. A summary of the timelines for the various meeting types is presented in the following table. Please note that the FDA review divisions are still implementing these changes, so there will be some flexibility in these requirements and timelines.

**Meeting****Description****Meeting Scheduled or Granted by FDA****Meeting or Written Response Date****Meeting Package Due**
Type AA meeting which is necessary for an otherwise stalled drug development program to proceed (a “critical path” meeting) or to address an important safety issue. \[Interpret as: stalled as a result of an FDA decision, not a sponsor business decision/situation\]Eg, a post-action meeting requested by the sponsor within three months after an FDA regulatory action other than an approval (ie, issuance of a complete response letter).Within 14 days of receipt of meeting requestWithin 30 days of receipt of requestAt time of meeting request letter
Type B- pre-IND - end of Phase 1 (for Subpart E or H) - end of Phase 2/pre-Phase 3 - a pre-NDA/BLA meeting. Each requestor should usually only request 1 each of these Type B meetings for each potential application. Within 21 days of receiving meeting request. PIND request may receive notification of written responses in place of meeting.Within 60 days of receipt of requestAt least 1 month in advance of meeting date
Type CAny other type of meeting.Within 21 days of receiving meeting request OR notification that written responses will be sent in place of meetingWithin 75 days of receipt of requestAt least 1 month in advance of meeting date
Special Protocol Question AssessmentUpon specific request by a sponsor the Agency will evaluate certain protocols and issues to assess whether the design is adequate to meet scientific and regulatory requirements. NAAgency response to questions within 45 daysNA
Complete Response to Clinical HoldComplete response to clinical hold (an order issued by FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation) requesting that the hold be removed.NAAgency response within 30 days of Sponsor’s complete responseNA
Notes:- These timelines are the goal for 90% of requests. - Meeting requests must be written (letter or fax). - FDA Meeting minutes will be available to Sponsor within 30 days of meeting date. - Draft guidance on formal meetings to be published no later than end of FY 2013.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights